NewsFeed Voices Science Insight Innovation
January, 2026
January 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Danielle Gilliam on FDA’s Approval of Wegovy Pill from Novo Nordisk
Danielle Gilliam/LinkedIn
Dec 24, 2025, 05:17

Danielle Gilliam on FDA’s Approval of Wegovy Pill from Novo Nordisk

Danielle Gilliam, Executive Medical Science Liaison Cardiovascular and Renal at Novo Nordisk North America, shared on LinkedIn:

”The FDA’s approval also clears the pill for use to reduce the risk of major cardiovascular events, such as death, heart attack or stroke, in adults with obesity and established cardiovascular disease, according to Novo Nordisk.”

Find more here.

Read the full announcement by Novo Nordisk here.

Novo Nordisk announced that the US Food and Drug Administration has approved the Wegovy pill, a once-daily oral semaglutide 25 mg, for long-term weight reduction and maintenance, as well as for reducing the risk of major adverse cardiovascular events.

The oral formulation is indicated for adults with obesity or overweight who have at least one weight-related comorbidity, and for adults with established heart disease to lower the risk of death, heart attack, or stroke.

In addition, Wegovy injection is approved for chronic weight management in paediatric patients aged 12 years and older.

The injectable form is also approved for the treatment of MASH in adults with moderate to advanced liver fibrosis, excluding those with cirrhosis.

Danielle Gilliam on FDA's Approval of Wegovy Pill from Novo Nordisk

Stay updated with Hemostasis Today.

Danielle Gilliam FDA Headlines Health Heart Attack Hematology Hemostasis Hemostasis Today Medicine Novo Nordisk Semaglutide stroke thrombosis Wegovy pill
NewsFeed